Hailshadow/iStock via Getty Images
- Royalty Pharma (RPRX) will provide $100M in funding to Zealand Pharma (ZLDPF) in exchange for a royalty for rusfertide (PTG-300), its candidate from the rare blood disease polycythemia vera.
- Terms call for Royalty to have rights to a 1% royalty on